MMF Shows Promise in Juvenile Scleroderma

Mycophenolate mofetil demonstrated comparable disease control with fewer adverse effects.

1

Mycophenolate mofetil (MMF) showed similar effectiveness to methotrexate (MTX) in treating juvenile localized scleroderma (JLS).
2

Patients treated with MMF experienced significantly fewer adverse effects compared to those receiving MTX, particularly regarding nausea and fatigue.
3

The study involved 114 patients with JLS, comparing outcomes of MTX, MMF, and combination therapy over a 12-month period.
4

Disease activity remained stable after corticosteroid discontinuation across all treatment groups, with a 25% flare rate overall.
5

The researchers recommend prospective, randomized trials to confirm MMF's potential as a first-line treatment for JLS.